HELIOS: IMBRUVICA® + BR for relapsed/ refractory CLL/SLL1

HELIOS: ORR in IMBRUVICA® + bendamustine and rituximab combination therapy for relapsed/refractory CLL/SLL1

Secondary endpoint: Overall response rate IMBRUVICA® + BR vs placebo + BR (N=578)1,2

Response (%)
  • Median follow-up was 17 months (N=578)2
  • ORR (complete response and partial response) was assessed by an IRC per iwCLL criteria2-4
  • 8.3% of patients who received IMBRUVICA® + BR achieved complete response vs 2.1% of patients who received placebo + BR1

Abbreviations

BR=bendamustine and rituximab, CLL=chronic lymphocytic leukemia, IRC=independent review committee, iwCLL=International Workshop on Chronic Lymphocytic Leukemia, ORR=overall response rate, SLL=small lymphocytic lymphoma.

References

1IMBRUVICA® (ibrutinib) Prescribing Information. 2Chanan-Khan A, Cramer P, Demirkan F, et al. lbrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211. 3Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute—Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456. 4Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes (e-Letter). Blood. 2012;119(23):5348.